XML 75 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration Agreements - Summary of Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 212,958 $ 130,996 $ 183,189
License Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 22,269 9,933 50,607
Development Revenue [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 125,913 121,063 132,582
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 14,323 0 9,548
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 0 0 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 2,400 1,588 4,288
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 18,503 18,523 17,487
AstraZeneca Agreements [Member] | China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 0 0 0
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue 7,946 9,933 41,059
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Total revenue $ 104,970 $ 100,928 $ 110,677